Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case information

Soleno Therapeutics Securities Fraud Class Action

Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.

Soleno Therapeutics · Diazoxide choline extended-release tablets (DCCR) · Ongoing Litigation

Last updated

Case overview

Defendant company
Soleno Therapeutics
Product or service
Diazoxide choline extended-release tablets (DCCR)
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead Plaintiff Application
Lead Plaintiff Application

Participation information

Availability is based on each listed participation option and its deadline.

Lead Plaintiff Application

Shareholders who purchased Soleno Therapeutics shares from March 26, 2025 through November 4, 2025 may have been eligible to seek lead plaintiff appointment.

Contact DJS Law Group regarding possible lead plaintiff appointment and participation in the case.

Type
Law Firm Signup
Status
Deadline passed
Reported proof requirement
Unclear

Lead Plaintiff Application

Investors who suffered losses related to Soleno Therapeutics securities may have sought appointment as lead plaintiff.

Contact the Law Offices of Frank R. Cruz to learn more or participate. The article states that class members do not need to take action to remain absent members of the class action.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Kahn Swick & Foti case information and contact page

Pomerantz LLP investor inquiry

Investors with losses on their investment in Soleno Therapeutics are advised to contact Pomerantz LLP.

Contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, or 888.4-POMLAW, toll-free, extension 7980. Email inquiries should include a mailing address, telephone number, and number of shares purchased.

Type
Law Firm Signup
Status
Unknown
Reported proof requirement
Unclear
Original press release Original article Original article Original article Original article

This information does not determine whether you qualify for a case.

Sources

Public reporting associated with this case.